Company news
Sarepta Therapeutics, Inc. news in 2022
Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
November 27, 2022
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 22, 2022
Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
November 1, 2022
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
October 25, 2022
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
October 6, 2022
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
September 28, 2022
Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
September 13, 2022
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
September 11, 2022
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
September 6, 2022
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
September 5, 2022
Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
August 7, 2022
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
August 1, 2022
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
July 28, 2022
Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
July 25, 2022
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
July 5, 2022
Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8: 30am ET
July 4, 2022
Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
June 22, 2022
Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 1, 2022
Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors
June 1, 2022
Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 3, 2022
Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
May 3, 2022
Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
April 26, 2022
Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program
March 7, 2022
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
February 28, 2022
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
February 21, 2022
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
January 31, 2022
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
January 9, 2022
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 5, 2022
Calls in 2022
Decks in 2022
- J.P. Morgan 40th Annual Healthcare Conference (January 2022)
Conference · 24 slides · Jan 10, 2022